1. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Abdulkhakov, Rustem; Abu ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Issue 10342 (11th June 2022) Authors: Sands, Bruce E; Irving, Peter M; Hoops, Timothy; Izanec, James L; Gao, Long-Long; Gasink, Christopher; Greenspan, Andrew; Allez, Matthieu; Danese, Silvio; Hanauer, Stephen B; Jairath, Vipul; Kuehbacher, Tanja; Lewis, James D; Loftus, Edward V; Mihaly, Emese; Panaccione, Remo; Scherl, Ellen; Shchu... Journal: Lancet Issue: Volume 399:Issue 10342(2022) Page Start: 2200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Egg Breakfast Diet vs. Clear Liquid Diet Before Colonoscopy: 188. (October 2019) Authors: Poudel, Rosina; Winstead, Nathaniel Journal: American journal of gastroenterology Issue: Volume 114 (2019)ACG Abstracts 1:Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗